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Greater access to highly active antiretroviral treatment (HAART) has increased the survival of people 
living with HIV and AIDS (PLWHA), and health-related quality of life (HRQoL) has emerged as an 
important indicator of treatment outcomes. However, the success of HAART depends on consistent and 
optimum adherence. Various cross-sectional studies and few longitudinal studies identified the 
relationship between HRQoL and HAART; however their association over time is still unclear. The 
objective of this study is to investigate the relationship between HRQoL and adherence to HAART over 
time. 431 PLWHAs were followed for one year at 4-monthly intervals. A descriptive adherence self-
report rating scale and WHOQOL-HIV BREF were administered to collect adherence and HRQoL data 
respectLYHO\2SWLPXPDGKHUHQFHZDVVHWDW5%. Significant differences (p<0.05) in the overall mean 
+54R/ VFRUHV RI WKH +$$57 DGKHUHQW  DQG QRQ-adherent (<95%) patients were observed 
amongst patients on HAART for the periods of 9-28 months, 49-64 months and 81-120 months. This 
study established a strong relationship between adherence to HAART and HRQoL over time. Adherence 
to HAART is still a challenge and needs to be addressed through appropriate interventions. 
 
Key words: Highly active antiretroviral therapy, health-related quality of life, medication adherence, interrupted 
time-series analysis, South Africa. 
 
 
INTRODUCTION 
 
HIV and AIDS has a devastating impact on morbidity 
and mortality across countries, with sub-Sahara Africa 
having the highest prevalence rates (WHO, 2014, 2018). 
Currently, 36.7 million people worldwide are living with 
HIV and AIDS, with 19.6 million people living in East and 
Southern Africa (Avert, 2017; US  Department  of  Health 
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and Human Services, 2018). Improved coverage and 
use of highly active antiretroviral treatment (HAART) has 
reduced morbidity and mortality in both children and 
adults with HIV and AIDS, with integrated approaches 
used to improve care and outcomes (Venter et al., 2017; 
Burrage et al., 2018). Improved care and an appreciable 
increase in access to HAART for people living with HIV 
and AIDS (PLWHA) have resulted in a 48% reduction in 
AIDS-related deaths since 2003, with the epidemic now 
declining (UNAIDS, 2017). Approximately 17 million 
PLWHA had access to HAART by end of 2015, and the 
global coverage of HAART has reached 46% (UNAIDS, 
2016). South Africa has a high burden of infectious 
diseases (Statistics South Africa, 2018), with an 
estimated 7.52 million PLWHA (Statistics South Africa, 
2018). Wider access to HAART through public health 
programs has resulted in life expectancy increasing from 
54.9 years in 2002 to 64.2 years in 2018 among people 
with HIV in South Africa, which is encouraging (Statistics 
South Africa, 2018).  
The evident effectiveness of HAART has resulted in an 
appreciable change in the patterns of mortality from HIV 
in South Africa, leading to increasing prevalence of HIV 
from 10.9% in 2002 to 12.6% in 2017 (Statistics South 
Africa, 2016).  The increased life expectancy denoted by 
an ageing HIV-infected population is also impacting on 
the rate of non-communicable diseases (NCDs) in South 
Africa and other African countries, with increasing rates 
of patients with both HIV and NCDs (Meyer et al., 2017; 
Rwegerera et al., 2017). Several studies identified that 
PLWHA may have a higher prevalence and early age of 
onset of NCDs compared to the general population 
(Guaraldi et al., 2011; Althoff et al., 2014; Schouten et 
al., 2014).  Treatment of NCDs poses challenges such 
as an increased pill burden impacting on adherence, 
increasing side-effects due to drug-drug interactions, as 
well as loss of treatment efficacy and subsequent 
virological breakthrough in patients with concomitant 
HIV, all of which may complicate HIV treatment (Deeks 
and Phillips, 2009; Althoff et al., 2016). With identified 
complexities relating to HAART and NCDs in PLWHA, 
coupled with reduced mortality, the focus over the last 
number of years has shifted to improving the health-
related quality of life (HRQoL) of PLWHA (Oguntibeju, 
2012; Van Tam et al., 2012; Balderson et al., 2013; 
Moorhouse, 2014; Owuor et al., 2014; Pasquau et al., 
2018) as a key outcome measure.         
Health-related quality of life (HRQoL) is one of the 
most used subjective aspects in assessing the impact of 
chronic disease conditions such as HIV, and is used as 
a key outcome variable for validating or reviewing 
current treatment approaches, assessing their 
effectiveness as well as in the approval of new 
therapeutic regimens (Geocze et al., 2010; Oguntibeju, 
2012; Balderson et al., 2013; Smit et al., 2015; Etenyi et 
al., 2018). Strict or  near  perfect  adherence  to  HAART  
 
 
 
 
 LVDOVRDNH\GHWHUPLQDQW LQRSWLPDO WKHUDSHXWLF
outcomes of HAART, with non-adherence to HAART 
likely to lead to therapeutic failure, immune system 
deterioration, emergence of resistant strains and sub-
optimal drug levels in the blood (Lyimo et al., 2012; 
Mghamba et al., 2013). This is a concern given still high 
prevalence rates for HIV and AIDS in sub-Saharan 
Africa, including South Africa. Published studies have 
also suggested that HAART potentially improves the 
HRQoL of patients, contributing to better adherence to 
HAART (Oguntibeju, 2012). Improved adherence will 
result in a greater suppression of the viral load and 
increased HRQoL (Campos et al., 2009). Although 
PLWHA experience the benefits of long-term use of 
HAART, various socio-demographic, clinical, 
psychological and behavioural determinants may 
negatively impact on their HRQoL (Degroote et al., 
2014). On the other hand, greater adherence may lead 
to increased toxicities, resulting in decreased HRQoL 
(Mannheimer et al., 2008; Ncama et al., 2008; Airoldi et 
al., 2010). Tenofovir disoproxil fumarate (TDF) 
containing regimens for instance are associated with 
both liver and kidney toxicities and efavirenz has been 
associated with neuropsychiatric side-effects (Gaida et 
al., 2016; Kalemeera et al., 2016; Kalemeera et al., 
2017; Mataranyika et al., 2017).  
Although the initiative to improve the care of patients in 
the public health system in South Africa through the 
introduction of National Health Insurance (NHI) (Meyer 
et al., 2017) has increased HAART coverage; there are 
still concerns about the provision of clinical care, 
including issues of adherence to medicines for patients 
with chronic diseases affecting their HRQoL with or 
without HIV (Meyer et al., 2017; Rampamba et al., 
2017).   
,W LV NQRZQ WKDW D SHUVRQ¶V +542/ LV LQIOXHQFHG E\
several determinants, and these determinants individually 
or simultaneously influence perceived HRQoL over time 
(Degroote et al., 2014). We are also aware that the 
relationship between HRQoL and HAART has been 
identified in high income countries. However, the 
relationship between HRQoL and long-term adherence 
to HAART is still unclear, especially in sub-Saharan 
African countries where the HIV population is very 
different to Western countries with a greater 
predominance of women (Gaida et al., 2016; Kalemeera 
et al., 2016). Furthermore, in these countries there is a 
high predominace of NCDs with high rates of obesity 
and hypertension (Cois and Day, 2015; Meyer et al., 
2017; Rampamba et al., 2017), and resources are 
constrained. Consequently, we sought to investigate the 
relationship between aspects of HRQoL and adherence 
to HAART over time in South Africa to provide future 
guidance.  
It is known that whilst a number of cross-sectional 
studies  and  longitudinal  studies  from  various  settings  
  
 
 
 
 
have indicated a correlation between HRQoL and 
adherence to HAART (Mannheimer et al., 2005; 
Burgoyne and Tan, 2008; Ncama et al., 2008; Airoldi et 
al., 2010; Bello SI and Bello IK, 2013; Cohen et al., 
2013; Silva et al., 2014; Vagiri et al., 2014), they have 
typically failed to establish a relationship over time due 
to the use of non-randomized convenience samples, 
insufficient sample size and use of HRQoL instruments 
not specific to PLWHA. They also failed to portray the 
HRQoL of patients according to the actual period of time 
they have been on HAART. We sought to address these 
deficiencies.  Most HRQoL studies conducted globally 
using the WHOQOL-HIV BREF in PLWHA have also 
been cross-sectional in nature and predominantly 
focused on the perceptions about HRQoL or a specific 
HRQoL domain and adherence to HAART (Belak 
.RYDƙHYLü HW DO  3HOW]HU and Phaswana-Mafuya, 
2008; Fatiregun et al., 2009; Rüütel et al., 2009; Saddki 
et al., 2009; Hsiung et al., 2011; Imam et al., 2011; Tran, 
2012; Bakiono et al., 2014; Vagiri et al., 2014; Tesfay et 
al., 2015; Surur et al., 2017).  
Our study is different as it identified changes in 
HRQoL over time, and sought to ascertain if there was a 
relationship between HRQoL and adherence behaviour 
over time on HAART. Regular and repeated assessment 
of HRQoL can be used to track changes in functional 
status over time, especially in chronic illnesses like HIV, 
as well as to evaluate and monitor treatment effects 
(Grossman et al., 2003). Although ART can result in 
better clinical outcomes and potentially improved 
HRQoL, side effects of ART and change in adherence 
behaviour can negatively influence HRQoL (Oguntibeju, 
2012). 
Consequently, to our best knowledge, we believe this 
is the first longitudinal study to study the relationship 
between HRQoL and adherence to HAART considering 
the exact period of time the patient has been on HAART. 
In view of this, we believe our findings may be of interest 
not only to key stakeholders in South Africa but also to 
other sub-Saharan African countries with a high burden 
of HIV, greater predominance of women with HIV, and 
struggling to attain or retain universal access to 
healthcare, given increasing rates of NCDs.  
 
 
MATERIALS AND METHODS 
 
Study design and sample  
 
This is a quantitative, longitudinal, cohort study conducted at 
Tshepang ARV Clinic at Dr George Mukhari Academic Hospital 
and the Tshwaraganang ARV Clinic at Phedisong 4 Community 
Health Centre between October 2013 and February 2015. Both 
study sites are in public sector settings situated north of Pretoria, 
are typical of such facilities throughout South Africa, and provide 
HAART for PLWHA.  
$WRWDORISDWLHQWV\HDUVZHUHVDPSOHGUDQGRPO\IURP
the register of patients scheduled for appointments at each of the 
two  study  sites  on  a  daily  basis  and  were  enrolled  within  the  
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following strata: i) newly-initiated on HAART; ii) 1 to 12 months on 
HAART; iii) 12 to 36 months on HAART; and iv) >36 months on 
HAART. 
nQuery Advisor® 6 software was used for the calculation of 
sample size. Sample size estimates were based on the following 
assumptions: i) 80% of subjects will report high levels of 
adherence and 20% will report lower levels of adherence; ii) a two-
group t-test with a 0.05 two-sided significance level will have 80% 
power to detect a difference in means of 6.0 in the HRQoL score 
between patients with high levels of adherence and those with 
lower levels of adherence will be clinically meaningful; and iii) an 
expected drop-out rate of 30%, based on experience from a 
previous studies conducted at study sites (Kadam and Bhalerao, 
2010; Noordzij et al., 2010).  Recruited patients were followed-up 
at 4-monthly intervals for a period of 12 months. At the end of the 
study period, 431 patients remained in the study and attended all 
study visits. 
 
 
Data collection and instruments  
 
Data were collected by four well trained data collectors, two at 
each clinic, while patients awaited consultation with heath care 
professionals. Most HRQoL questionnaires specific to HIV and 
AIDS are long forms with an in-depth analysis of well-being, 
resulting in PLWHA being burdened with a long and time-
consuming QoL assessment. The WHOQOL-HIV BREF was 
identified as the most suitable HRQoL questionnaire for this study 
due to its HIV and AIDS specificity, provides a snap shot of 
HRQoL, has the ability to distinguish between different stages of 
HIV disease progression, has good psychometric properties and 
has discriminant validity (Meemon et al., 2016; Tesfaye et al., 
2016). The completion and administration process of the 
questionnaire is simple, providing a quick measure of HRQoL; 
consequently, making it ideal for administration to PLWHA in busy 
FOLQLFV 2¶&RQQHOO DQG 6NHYLQJWRQ  ,Q DGGition, the 
WHOQOL-HIV BREF had already been translated into different 
languages and validated in different study and cultural settings 
across multiple countries (Belak et al., 2006; Peltzer and 
Phaswana-Mafuya, 2008; Fatiregun et al., 2009; Rüütel et al., 
2009; Saddki et al., 2009; Hsiung et al., 2011; Imam et al., 2011; 
Tran, 2012; Bakiono et al., 2014; Vagiri et al., 2014; Tesfay et al., 
2015; Surur et al., 2017). 
The WHOQOL-HIV BREF is a multi-dimensional instrument 
comprising 31-items covering six domains; namely, physical, 
psychological, level of independence, social relationships, 
environment, and spirituality/religion/personal beliefs. The 
WHOQOL-HIV BREF is based on the shorter WHOQOL-BREF 
which is an abbreviated version of the WHOQOL-100.  Each 
domain has a set of facets and denotes a description of a 
behaviour, a state of being, a capacity or potential, or a subjective 
SHUFHSWLRQ RU H[SHULHQFH 2¶&RQQHOO DQG 6NHYLQJWRQ 
Individual items on the WHOQOL-HIV BREF were rated on a five-
point Likert scale, ranging from one (low or negative perception) to 
five (high or positive perception). 
Socio-demographic data, health-related characteristics and 
adherence data were obtained using an interviewer-administered 
questionnaire. Questions included in the socio-demographic 
questionnaire were based on previous studies conducted at 
Tshepang Clinic (Mapetla, 2007; Engelbrecht, 2010; Meyer et al., 
2012), as well as with consideration of the literature (Belak 
.RYDƙHYLüHWDO+DVDQDKHWDO 
Adherence measures for this study were identified based on 
adherence measures reported in the literature and those used in 
previous studies conducted at Tshepang Clinic (Chesney et al., 
2000; Mapetla, 2007; Amico et al., 2009; Wilson et al., 2009; Berg 
et al., 2010;  Engelbrecht,  2010;  Meyer  et   al.,   2012). Recall on  
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adherence to HAART over the past 30 days was determined using 
a self-reported descriptive rating scale with six response options: 
excellent, very good, good, fair, poor, and very poor.  This 
particular rating scale was used to measure adherence as 
previous research using cognitive testing indicated that 
respondents felt more comfortable and confident with words 
(adjectives and adverbs) compared to numbers. Cognitive 
estimation of adherence has also matched better with words than 
with numbers (Wilson et al., 2014; Phillips et al., 2017). Numeric 
values were assigned to patient-reported adherence ratings based 
on previous studies conducted at the study sites and published 
studies on adherence (Mapetla, 2007; Lu et al., 2008; Engelbrecht, 
2010; Buscher et al., 2011; Vagiri et al., 2014). This was also 
supported by our previous study comparing patient-reported 
adherence ratings with assigned numeric values,  which proved 
ideal in a cross-sectional study conducted with 110 PLWHA at one 
of the study sites (Tshepang HAART Clinic) (Vagiri et al., 2014). 
The cognitive process of adherence estimation matched better 
with the words, and assigned numeric values correlated with 
patient-reported adherence ratings, which supported the use of the 
rating scale as a self-report adherence measure in a resource-
limited setting (Vagiri et al., 2014). 
The data collection instruments were available in English and in 
Setswana, a local language predominantly spoken in the area 
where the study was conducted. Forward and back translation of 
the instruments was performed by two bi-lingual health 
professionals to provide cross-cultural equivalence. The 
questionnaires were pilot-tested for feasibility and administered to 
a sample of 110 PLWHA in an initial cross-sectional study 
previously conducted at one of the study sites (Tshepang HAART 
Clinic) (Vagiri et al., 2014). Based on the results of the pilot test, 
only the adherence questions were amended prior to the 
commencement of this longitudinal study.    
Both the HRQoL and the self-reported adherence rating scale 
were administered to patients at baseline (Visit 1), and at follow-up 
visits after 4 months (Visit 2), 8 months (Visit 3) and 12 months 
(Visit 4). The self-reported adherence rating scale was not 
administered to patients who were still treatment-naïve at baseline. 
Socio-demographic and health-related characteristics data were 
obtained only at baseline. Patients who missed any, or all, of the 
follow-up study visits over the 12-month study period were 
excluded from the data analysis as each patient served as their 
own control.        
 
 
Ethical approval 
 
All procedures performed in studies involving human participants 
were in accordance with the ethical standards of the institutions. 
Permission to conduct the study was obtained from the 
management of the two study sites and ethical clearance was 
granted by the Medunsa Campus Research Ethics Committee of 
the University of Limpopo (MREC/H/160/2008:PG) and Tshwane 
Research and Ethics Committee (Project: 2012/16). 
 
 
Data analysis 
 
Data were captured into a Microsoft Office ExcelTM spreadsheet, 
verified for correctness and cleaned, after which it was exported to 
Statistical Package for the Social Sciences (SPSS) Version 20.0 
for analysis. Socio-demographic data, health-related characteristics 
data and adherence data were summarised and expressed as 
frequencies and percentages. The patient-reported adherence 
ratings were also converted to a percentage as follows: excellent 
(100%), very good (95%), good (90%), fair (80%), poor (70%), and  
 
 
 
 
very poor (<70%) in line with previous studies (Mapetla, 2007; Lu 
et al., 2008; Engelbrecht, 2010; Buscher et al., 2011, Vagiri et al., 
2SWLPDODGKHUHQFHZDVVHWDWLQ WKLVVWXG\7XUQHU
2002; WHO, 2006). Patients wLWK DGKHUHQFH UHSRUWHG DV µYHU\
JRRG¶ DQG µH[FHOOHQW¶ RQ WKH UDWLQJ VFDOH ZHUH FODVVLILHG DV
DGKHUHQWDQGWKRVHZLWKDGKHUHQFHUDWLQJVRIµJRRG¶µIDLU¶
µSRRU¶ DQG µYHU\ SRRU¶ ZHUH FODVVLILHG DV QRQ-adherent (<95%) 
(Feldman et al., 2013).  
All HRQoL domain scores, ranging from one (low or negative 
perception) to five (high or positive perception), were multiplied by 
four to enable the scores range from four to 20 (All scores are 
multiplied by 4 so as to be directly comparable with scores derived 
from the WHOQOL-100). The mean HRQoL domain scores were 
then averaged to obtain an overall HRQoL score.  
An interrupted time-series analysis was conducted to identify the 
association between adherence and mean HRQoL for the actual 
duration a patient had been on HAART (Velicer and Fava, 2003). 
The adherence and HRQoL responses of all patients for the four 
study visits were pooled to obtain a combined sample (n=1631, 
excluding 93 treatment-naïve patients). All scores were regrouped 
into 4-monthly intervals, accoUGLQJ WR WKH SDWLHQW¶V H[DFW GXUDWLRQ
on HAART (ranging from 1 to 120 months). Overall mean HRQoL 
was compared for patients classified as adherent and non-
adherent (<95%) for each time interval, using an independent 
sample t-test, with statistical significance set at pCohen's d 
test was employed to measure appropriate effect size of mean 
HRQoL scores between adherent and non-adherent patients. 
 
 
RESULTS 
 
Removing patients who missed any, or all, of the follow-
up study visits over the 12-month study period resulted 
in a 23.6% (n=132) drop-out rate leaving a final sample 
size of 431 patients. 
The majority of the participants were females (76.1%), 
completed secondary education (74.2%), lived in a 
family (87.9%), did not consider themselves ill (88.2%) 
and attended associations supporting HIV and AIDS 
(81.9%). More than half of the subjects were middle-
aged (62.2%), Single (68.7%), unemployed (56.1%), 
asymptomatic (60.3%) and reported good health 
(54.0%). Just over a third of the patients did not have 
any income (36.4%) and 27.8% reported to be living with 
other HIV and AIDS patients. The mean age of the 
sample at baseline was 38.5 years (SD: 8.45) (Table 1). 
From Table 2, it is evident that more than three-
quarters (76.2%) of patients reported being highly 
DGKHUHQWWR+$$57 
A gradual increase in the proportion of adherent 
 SDWLHQWV ZDV REVHUYHG RYHU WLPH IURP 9LVLW 
(69.5%) to Visit 4 (81.6%) after 12 months (Figure 1). 
Based on the self-reported adherence rating scale, all 
patient grRXSVZKRUHSRUWHGDGKHUHQFH UHSRUWHG
higher overall mean HRQoL compared to those <95% 
adherent, except for patients newly initiated on HAART 
(1-4 months) and those 41-44 months on HAART 
(Figure 2). Relatively low and very similar overall HRQoL 
was reported by adherent and non-adherent patients 
within  the  first  4  months  of  HAART  (15.93 and 15.97  
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Table 1. Socio-demographic and health status characteristics of the study sample at baseline (n=431). 
 
Socio-demographic and health status characteristics Frequency (%) 
Gender Male 103 (23.9) Female 328 (76.1) 
 
  
Age (in years) 
- <31 76 (17.6) 
- <46 268 (62.2) 
 87 (20.2) 
 
  
Clinical status Asymptomatic 260 (60.3) Symptomatic/AIDS 171 (39.7) 
 
  
Education 
Primary (Grade 0 ± 7) 78 (18.1) 
Secondary (Grade 8 ± 12) 320 (74.2) 
Tertiary 33 (7.7) 
 
  
Employment Unemployed 242 (56.1) Employed 189 (43.9) 
 
  
Marital status 
Single 296 (68.7) 
Married 87 (20.2) 
Divorced/Separated/Widowed 48 (11.1) 
 
  
Income (in ZAR) 
None 157 (36.4) 
R1 - R2000 187 (43.4) 
R2001 - R5000 63 (14.6) 
More than R5000 24 (5.6) 
 
  
Self-rated health status 
Good 362 (84.0) 
Neither poor nor good 59 (13.7) 
Poor 10 (2.3) 
 
  
Consider oneself as ill Yes 51 (11.8) 
No 380 (88.2) 
 
 
 
respectively). This could potentially be explained by 
SDWLHQWV¶ FOLQLFDO +,9 VWDWXV DW WKH VWDUW RI +$$57
$OWKRXJK WKHRYHUDOOPHDQ+54R/ IRUDGKHUHQW 
patients was lower than <95% adherent patients in the 
group 41-44 months on ART, this difference was not 
statistically significant (p=0.433) (Table 3). 
Overall, a statistically significant  difference in the 
PHDQ +54R/ VFRUHV RI +$$57 DGKHUHQW  DQG
non-adherent (<95%) patients was observed amongst 
patients on HAART for the periods 9-28 months, 49-64 
months and 81-120 months on treatment (Table 3; 
Figure 2). The significant differences in mean HRQoL 
scores between adherent and non-adherent patients 
was further confirmed by CohHQ¶V d test, with effect 
sizes ranging from medium to large (Table 3). 
 
 
DISCUSSION 
 
The high percentage of women in our study confirms 
other studies showing higher rates of HIV among women 
in sub-Saharan Africa compared with men, which is 
different to the characteristics of patients with HIV in high 
income countries (Gaida et al., 2016; Kalemeera et al., 
2016). 
Encouragingly, three quarters of the patients (76.3%) 
LQWKLVVWXG\UDWHGWKHLUDGKHUHQFHDV³H[FHOOHQW´RU³YHU\
JRRG´ RQ WKH GHVFULSWLYH patient-reported adherence 
rating scale; while very few patients (0.5%) rated their 
DGKHUHQFH DV ³SRRU´ RU ³YHU\ SRRU´ $OWKRXJK H[FHOOHQW
DGKHUHQFH RI  LV UHTXLUHG IRU +$$57 a 
contributing factor to the appreciable number of patients 
in this study reporting good adherence could be the 
introduction of a fixed-dose combination (FDC) 
containing tenofovir, emtricitabine and efavirenz as a 
first-line regimen during 2013 by the National 
Department of Health (NDoH) in South Africa. Fixed-
dose combinations are known to reduce pill burden, are 
convenient to take, and evidently promote adherence    
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Table 2. Levels of adherence (n=1629). 
 
Adherence rating (%) No. (%)a 
Poor (70%) 8 (0.5)b 
Fair (80%) 31 (1.9) 
Good (90%) 347 (21.3) 
Very Good (95%) 804 (49.4) 
Excellent (100%) 439 (26.9) 
 
a93 patients were treatment-naïve at Visit 1 (baseline), therefore could not rate their 
adherence; bTwo of the 8 patients reported their adherence as very poor (<70%). 
 
 
 
 
 
Figure 1. Level of adherence over time at different study visits (n=431). 
 
 
 
(Farrel et al., 2013;  Feldman  et  al., 2013; Vrijens et al., 
2017). This though needs to be explored further before 
any definitive statements can be made especially as 
some of these patients will have co-morbidities increasing 
their pill burden. In our study, chronic co-morbidities and 
co-infections were not recorded, yet their treatment may 
KDYHDIIHFWHGSDWLHQWV¶DGKHrence to HAART. 
An improvement in HRQoL over time has been 
elucidated in a number of longitudinal studies; however, 
the results varied across different research settings. 
Mannheimer et al. (2005) reported a significant 
association between adherence and HRQoL in a 12-
month prospective, longitudinal study conducted in the 
USA with 1050 HIV treatment-experienced patients. 
HRQoL was measured using the SF-12 Health Survey 
instrument and was administered at baseline, one, four, 
eight and 12 months respectively.  The results described 
a significant improvement of HRQoL at the first, fourth 
and twelfth months. Participants who reported 100% 
adherence   to    HAART    reported   significantly   higher 
HRQoL at 12 months compared to those with poorer 
adherence. As a result, this study also provided evidence 
that HAART, if taken as prescribed, has a positive effect 
on QoL similar to our findings (Mannheimer et al., 2008).   
Another longitudinal study conducted in Brazil with 
treatment naïve patients included one baseline interview 
and three follow-up interviews at the first, fourth and 
seventh month thereafter. The baseline interview 
assessed socio-demographic, treatment-related and 
behavioural characteristics, while follow-up interviews 
evaluated adherence and HRQoL (assessed using 
WHOQOL-BREF). The results demonstrated a significant 
improvement in QoL after four months on HAART. Two-
thirds (66.4%) of the patients reported good or very good 
QoL suggesting an improvement of HRQoL after initiating 
treatment (Campos et al., 2009).  This study supports our 
study finding that better adherence results in increased 
QoL. 
In our study, patients who UHSRUWHG  DGKHUHQFH 
reported better HRQoL compared to patients who reported 
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Table 3. Comparison of mean HRQoL VFRUHV EHWZHHQ DGKHUHQW  DQG QRQ-adherent (<95%) patients and their effect 
sizes. 
 
Patient  group Adherence rate category n Mean HRQoL (SD) T p* D 
1-4 months 
$GKHUHQW 38 15.93 (0.65) 
-0.3 0.792 0.06 
Non-adherent (<95%) 58 15.97 (0.68) 
5-8 months 
$GKHUHQW 54 16.09 (0.67) 
0.5 0.594 0.09 
Non-adherent (<95%) 87 16.03 (0.66) 
9-12 months 
$GKHUHQW 66 16.23 (0.91) 
2.1 0.033 0.33 
Non-adherent (<95%) 102 15.94 (0.85) 
13-16 months 
$GKHUHQW 46 16.46 (1.11) 
2.7 0.007 0.53 
Non-adherent (<95%) 66 15.90 (1.01) 
17-20 months 
$GKHUHQW 41 16.52 (1.21) 
3.1 0.003 0.61 
Non-adherent (<95%) 62 15.82 (1.05) 
21-24 months 
$GKHUHQW 39 16.52 (1.25) 
3.2 0.002 0.67 
Non-adherent (<95%) 55 15.72 (1.14) 
25-28 months 
$GKHUHQW 42 16.51 (1.06) 
2.5 0.012 0.51 
Non-adherent (<95%) 65 15.95 (1.12) 
29-32 months 
$GKHUHQW 38 16.35 (1.43) 
1.4 0.162 0.27 
Non-adherent (<95%) 68 16.00 (1.12) 
33-36 months 
$GKHUHQW 43 16.26 (1.41) 
0.7 0.495 0.13 
Non-adherent (<95%) 63 16.10 (1.09) 
37-40 months 
$GKHUHQW 39 16.29 (1.48) 
0.6 0.575 0.12 
Non-adherent (<95%) 52 16.13 (1.19) 
41-44 months 
$GKHUHQW 27 15.78 (1.92) 
-0.8 0.433 0.19 
Non-adherent (<95%) 34 16.08 (1.03) 
45-48 months 
$GKHUHQW 26 16.33 (1.64) 
1.2 0.231 0.33 
Non-adherent (<95%) 26 15.87 (1.06) 
49-52 months 
$GKHUHQW 17 16.56 (1.88) 
2.1 0.041 0.65 
Non-adherent (<95%) 23 15.57 (1.06) 
53-56 months 
$GKHUHQW 20 16.59 (1.92) 
2.2 0.033 0.67 
Non-adherent (<95%) 22 15.53 (1.13) 
57-60 months 
$GKHUHQW 19 17.04 (1.25) 
4.0 0.000 1.25 
Non-adherent (<95%) 22 15.44 (1.30) 
61-64 months 
$GKHUHQW 13 16.98 (1.28) 
2.9 0.008 1.07 
Non-adherent (<95%) 16 15.52 (1.44) 
65-68 months 
$GKHUHQW 13 16.32 (1.44) 
1.3 0.205 0.48 
Non-adherent (<95%) 16 15.63 (1.42) 
69-72 months 
$GKHUHQW 11 16.22 (1.06) 
1.4 0.175 0.53 
Non-adherent (<95%) 20 15.63 (1.17) 
73-76 months 
$GKHUHQW 15 15.98 (1.43) 
0.9 0.396 0.32 
Non-adherent (<95%) 14 15.58 (1.03) 
77-80 months 
$GKHUHQW 15 15.94 (1.44) 
1.1 0.302 0.35 
Non-adherent (<95%) 20 15.46 (1.27) 
81-120 months 
$GKHUHQW 43 16.48 (1.23) 
4.2 0.000 0.79 
Non-adherent (<95%) 75 15.58 (1.04) 
All patient groups 
$GKHUHQW 704 16.31 (1.26) 
7.9 0.000 0.38 
Non-adherent (<95%) 1020 15.87 (1.03) 
 
*p<0.05, Independent sample t-test; SD: Standard deviation; d: &RKHQ¶VG for Independent sample t-test. 
 
 
 
<95% over a period of 12 months (Table 2). We know 
HAART potentially improves HRQoL and contributes to 
enhanced treatment via better adherence to HAART (Smit 
et al., 2015; Mataranyika et al., 2018). 
This finding was supported by a multi-site cohort study 
conducted in the USA where PLWHA who had a 
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Figure 2. Time series analysis comparing level of adherence and mean HRQoL over time (n=1631). 
 
 
 
meaningful, comfortable life, who were well cared 
for, and who used their time wisely, reported 
better adherence to their treatment (Liu et al., 
2013). In addition, better adherence is known to 
result  in   greater   suppression  of  the  virus  and 
results in increased HRQoL (Lyimo et al., 2012). 
This association between adherence to HAART 
and HRQoL is further confirmed by the results of 
our time-series analysis (Figure 2). Irrespective of 
the time on HAART, it was revealed that adherent 
patients      consistently    reported   better  
HRQoL compared to the non-adherent patients.  
It is recognise though that consideration of the 
role of social capital in adherence to HAART 
needs to be better understood in South Africa 
building on previous research (Binagwaho and 
Ratnayake,  2009;  Jakovljevic  and   Milovanovic, 
2015), and this will be investigated further in future 
  
 
 
 
 
studies. It is also known that this study had some 
limitations. Firstly, it was conducted at only two 
treatment centres, hence the results cannot be 
generalised to the entire country, although we believe 
patients attending these two clinics are typical of those 
attending public health clinics throughout South Africa. 
Secondly, the drop-out rate over the 12-month follow-up 
period, as well as recall and social desirability bias due 
to patient self-report on adherence and HRQoL, could 
have inflated some of the data. Thirdly, numeric values 
were assigned to patient-reported adherence ratings, 
which may have influenced levels of adherence 
presented; although, this did not have an effect on actual 
FDWHJRULVDWLRQ RI DGKHUHQW  DQG QRQ-adherent 
patients (<95%) as optimal adherence for this study was 
VHW DW  DFFRUGLQJ WR :+2 DGKHUHQFH JXLGHOLQHV
(WHO, 2006). However, despite these limitations, we 
believe our findings are robust in view of the 
methodology we employed. 
 
 
Conclusion 
 
Encouragingly, there were high adherence rates to 
HAART in this study, with this study establishing a 
significant relationship between HRQoL and adherence 
to HAART over time. Adherent patients consistently 
reported better HRQoL compared to the non-adherers 
irrespective of the period of time on HAART, underlining 
the importance of adherence in improving HRQoL in 
patients with HIV. Adherence to HAART is complex and 
it is a dynamic and biosocial process influenced by 
diverse factors influencing HRQoL in a positive or 
negative manner. As HAART is a lifelong treatment, 
DVVHVVLQJSDWLHQWV¶DGKHUHQFHEHKDYLRXUDQG LPSURYLQJ
adherence will maximise the benefits of HAART and 
HQKDQFH SDWLHQWV¶ +54R/ 7KLV EXLOGV RQ WKH 6RXWK
$IULFDQJRYHUQPHQW¶VLQLWLDWLYHVWRLPSURYHDGKHUHQFHWR
HAART. Whilst HAART increases the lifespan of 
PLWHA, their HRQoL remains a concern. This can be 
improved with improved adherence. Understanding the 
social consequences of this disease, and making 
appropriate clinical interventions, can also improve 
HRQoL, and we will be exploring this further in future 
research. 
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